Cargando…

Development of a Ternary Solid Dispersion Formulation of LW6 to Improve the In Vivo Activity as a BCRP Inhibitor: Preparation and In Vitro/In Vivo Characterization

LW6 (3-[2-(4-adamantan-1-yl-phenoxy)-acetylamino]-4-hydroxy-benzoic acid methyl ester) is a potent inhibitor of drug efflux by the breast cancer resistance protein (BCRP). However, its poor aqueous solubility leads to low bioavailability, which currently limits in vivo applications. Therefore, the p...

Descripción completa

Detalles Bibliográficos
Autores principales: Bajracharya, Rajiv, Lee, Sang Hoon, Song, Jae Geun, Kim, Minkyoung, Lee, Kyeong, Han, Hyo-Kyung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6572573/
https://www.ncbi.nlm.nih.gov/pubmed/31052438
http://dx.doi.org/10.3390/pharmaceutics11050206
_version_ 1783427672033984512
author Bajracharya, Rajiv
Lee, Sang Hoon
Song, Jae Geun
Kim, Minkyoung
Lee, Kyeong
Han, Hyo-Kyung
author_facet Bajracharya, Rajiv
Lee, Sang Hoon
Song, Jae Geun
Kim, Minkyoung
Lee, Kyeong
Han, Hyo-Kyung
author_sort Bajracharya, Rajiv
collection PubMed
description LW6 (3-[2-(4-adamantan-1-yl-phenoxy)-acetylamino]-4-hydroxy-benzoic acid methyl ester) is a potent inhibitor of drug efflux by the breast cancer resistance protein (BCRP). However, its poor aqueous solubility leads to low bioavailability, which currently limits in vivo applications. Therefore, the present study aimed to develop ternary solid dispersion (SD) formulations in order to enhance the aqueous solubility and dissolution rate of LW6. Various SDs of LW6 were prepared using a solvent evaporation method with different drug/excipient ratios. The solubility and dissolution profiles of LW6 in different SDs were examined, and F8-SD which is composed of LW6, poloxamer 407, and povidone K30 at a weight ratio of 1:5:8 was selected as the optimal SD. The structural characteristics of F8-SD were also examined using Fourier transform infrared spectroscopy (FTIR), differential scanning calorimetry (DSC), X-ray powder diffraction (XRPD), and scanning electron microscopy (SEM). In the acidic to neutral pH range, F8-SD achieved rapid dissolution with a drug release of 76–81% within 20 min, while the dissolution of pure LW6 was negligible. The XRPD patterns indicated that F8-SD probably enhanced the solubility and dissolution of LW6 by changing the drug crystallinity to an amorphous state, in addition to the solubilizing effect of the hydrophilic carriers. Furthermore, F8-SD significantly improved the oral bioavailability of topotecan, which is a BCRP substrate, in rats. The systemic exposure of topotecan was enhanced approximately 10-fold by the concurrent use of F8-SD. In conclusion, the ternary SD formulation of LW6 with povidone K30 and poloxamer 407 appeared to be effective at improving the dissolution and in vivo effects of LW6 as a BCRP inhibitor.
format Online
Article
Text
id pubmed-6572573
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-65725732019-06-18 Development of a Ternary Solid Dispersion Formulation of LW6 to Improve the In Vivo Activity as a BCRP Inhibitor: Preparation and In Vitro/In Vivo Characterization Bajracharya, Rajiv Lee, Sang Hoon Song, Jae Geun Kim, Minkyoung Lee, Kyeong Han, Hyo-Kyung Pharmaceutics Article LW6 (3-[2-(4-adamantan-1-yl-phenoxy)-acetylamino]-4-hydroxy-benzoic acid methyl ester) is a potent inhibitor of drug efflux by the breast cancer resistance protein (BCRP). However, its poor aqueous solubility leads to low bioavailability, which currently limits in vivo applications. Therefore, the present study aimed to develop ternary solid dispersion (SD) formulations in order to enhance the aqueous solubility and dissolution rate of LW6. Various SDs of LW6 were prepared using a solvent evaporation method with different drug/excipient ratios. The solubility and dissolution profiles of LW6 in different SDs were examined, and F8-SD which is composed of LW6, poloxamer 407, and povidone K30 at a weight ratio of 1:5:8 was selected as the optimal SD. The structural characteristics of F8-SD were also examined using Fourier transform infrared spectroscopy (FTIR), differential scanning calorimetry (DSC), X-ray powder diffraction (XRPD), and scanning electron microscopy (SEM). In the acidic to neutral pH range, F8-SD achieved rapid dissolution with a drug release of 76–81% within 20 min, while the dissolution of pure LW6 was negligible. The XRPD patterns indicated that F8-SD probably enhanced the solubility and dissolution of LW6 by changing the drug crystallinity to an amorphous state, in addition to the solubilizing effect of the hydrophilic carriers. Furthermore, F8-SD significantly improved the oral bioavailability of topotecan, which is a BCRP substrate, in rats. The systemic exposure of topotecan was enhanced approximately 10-fold by the concurrent use of F8-SD. In conclusion, the ternary SD formulation of LW6 with povidone K30 and poloxamer 407 appeared to be effective at improving the dissolution and in vivo effects of LW6 as a BCRP inhibitor. MDPI 2019-05-01 /pmc/articles/PMC6572573/ /pubmed/31052438 http://dx.doi.org/10.3390/pharmaceutics11050206 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Bajracharya, Rajiv
Lee, Sang Hoon
Song, Jae Geun
Kim, Minkyoung
Lee, Kyeong
Han, Hyo-Kyung
Development of a Ternary Solid Dispersion Formulation of LW6 to Improve the In Vivo Activity as a BCRP Inhibitor: Preparation and In Vitro/In Vivo Characterization
title Development of a Ternary Solid Dispersion Formulation of LW6 to Improve the In Vivo Activity as a BCRP Inhibitor: Preparation and In Vitro/In Vivo Characterization
title_full Development of a Ternary Solid Dispersion Formulation of LW6 to Improve the In Vivo Activity as a BCRP Inhibitor: Preparation and In Vitro/In Vivo Characterization
title_fullStr Development of a Ternary Solid Dispersion Formulation of LW6 to Improve the In Vivo Activity as a BCRP Inhibitor: Preparation and In Vitro/In Vivo Characterization
title_full_unstemmed Development of a Ternary Solid Dispersion Formulation of LW6 to Improve the In Vivo Activity as a BCRP Inhibitor: Preparation and In Vitro/In Vivo Characterization
title_short Development of a Ternary Solid Dispersion Formulation of LW6 to Improve the In Vivo Activity as a BCRP Inhibitor: Preparation and In Vitro/In Vivo Characterization
title_sort development of a ternary solid dispersion formulation of lw6 to improve the in vivo activity as a bcrp inhibitor: preparation and in vitro/in vivo characterization
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6572573/
https://www.ncbi.nlm.nih.gov/pubmed/31052438
http://dx.doi.org/10.3390/pharmaceutics11050206
work_keys_str_mv AT bajracharyarajiv developmentofaternarysoliddispersionformulationoflw6toimprovetheinvivoactivityasabcrpinhibitorpreparationandinvitroinvivocharacterization
AT leesanghoon developmentofaternarysoliddispersionformulationoflw6toimprovetheinvivoactivityasabcrpinhibitorpreparationandinvitroinvivocharacterization
AT songjaegeun developmentofaternarysoliddispersionformulationoflw6toimprovetheinvivoactivityasabcrpinhibitorpreparationandinvitroinvivocharacterization
AT kimminkyoung developmentofaternarysoliddispersionformulationoflw6toimprovetheinvivoactivityasabcrpinhibitorpreparationandinvitroinvivocharacterization
AT leekyeong developmentofaternarysoliddispersionformulationoflw6toimprovetheinvivoactivityasabcrpinhibitorpreparationandinvitroinvivocharacterization
AT hanhyokyung developmentofaternarysoliddispersionformulationoflw6toimprovetheinvivoactivityasabcrpinhibitorpreparationandinvitroinvivocharacterization